Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction

This study has been completed.
European Commission
Information provided by (Responsible Party):
Trophos Identifier:
First received: June 14, 2011
Last updated: November 21, 2013
Last verified: November 2013

June 14, 2011
November 21, 2013
October 2011
September 2013   (Final data collection date for primary outcome measure)
Infarct size expressed as area under the curve for Creatine kinase and Troponin I [ Time Frame: Blood samples will be collected at admission and every 6 hours until 72h ]
Same as current
Complete list of historical versions of study NCT01374321 on Archive Site
Infarct size evaluated by Cardiac Magnetic Resonance [ Time Frame: A cardiac magnetic resonance between day 3 and Day 5 after balloon inflation ]
Same as current
Not Provided
Not Provided
Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction
Phase II, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction

Objectives of the phase 2 prospective, multicenter, randomized, double-blind, placebo-controlled study is to assess safety and efficacy of TRO40303 administered just before balloon inflation during percutaneous coronary intervention (PCI) for limitation of infarct size in patients treated for acute myocardial infarction (AMI).

The study is being conducted in 9 centres in Sweden, Denmark, Norway and France. One hundred eighty patients will be included. It will last one month per patient and its overall duration will be 11 months.

The efficacy will be assessed by infarct size expressed as area under the curve for creatine kinase and troponin I (blood sampling at D1, D2 and D3), and also evaluated by Cardiac Magnetic Resonance.

Safety will be assessed by

  • clinic evaluation,
  • blood samples (hematology, biochemistry, renal and hepatic function),
  • Recording and follow-up of major adverse events occurring during the first 48h after reperfusion (death, heart failure, AMI, stroke, recurrent ischemia, the need for repeat revascularization, renal or hepatic, vascular complication and bleeding).
  • ECG
  • Recording cardiac events during one month after AMI
  • Follow-up of global left ventricular function by Echocardiography at D3 and D30.

Demographic and medical history at inclusion and non-cardiac events occurring during the first 30 days will be recorded. TRO40303 plasma concentration will be assessed at 15 min, 6h, and 12h post the end of administration.

Sample size calculation assuming a reduction of 35% of the AUC for Troponin I release, for a statistical power of 85% and a probability of type I error of 0.05.

Main analysis: between-group comparisons of AUCs for serum troponin I and CK release will be performed using O'Brien's method for multiple endpoints testing.

Secondary analysis: comparisons of the CMR criteria described above will be performed using mixed model of ANCOVA.

All analyses will be performed on the Full Analysis Set and Per protocol populations.

Safety analysis: A comparison of the incidence of cumulative adverse clinical events between the groups will be performed by Fisher's exact tests.

Subjects will undergo primary PCI and receive concomitant medications according to current standard of care.

After coronary angiography is performed but just before balloon inflation is performed, patients who meet the enrollment criteria will be randomly assigned to either the control group or the TRO40303 group. Randomization is ensured by taking the treatment units in ascending and consecutive order in each strata (anterior/posterior as determined on ECG). Just before balloon inflation, ideally less than 5 minutes, and with a maximum of 15 minutes before balloon inflation and stenting, the patients in the TRO40303 group will receive an intravenous slow-bolus (35 mL/min) injection of 6 mg/kg of TRO40303 injected in peripheral IV. The patients in the control group will receive an equivalent volume of the placebo. Patients will be hospitalized for as long as there is a medical indication. CMR and echocardiography will accordingly be conducted as in/out patient between day 3 (ideally) and 5. A follow-up visit will be conducted one month after PCI.

Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Acute Myocardial Infarctus
  • Drug: TRO40303
    6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
  • Drug: Placebo
    single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: TRO40303
    Intervention: Drug: TRO40303

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
September 2013
September 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male and Female with non childbearing potential patients
  2. Age > 18 years old
  3. First acute myocardial infarction
  4. Occlusion should affect the following coronary arteries: LAD,or the dominant or balanced RCA, or the dominant or balanced LCx
  5. Acute myocardial infarction defined as

    • nitrate resistant chest pain ≥ 30 min
    • ST elevation: New ST elevation at the J-point in two contiguous leads with the cut-off points: ≥ 2 mV in men or ≥ 0.15 mV in women in leads V2-V3 and/or ≥ O.1 mV in other leads
  6. Presenting within 6h of onset of chest pain
  7. Clinical decision to treat with percutaneous coronary intervention
  8. Occlusion of culprit artery with a Thrombolysis In Myocardial Infarction (TIMI) flow grade 0-1 at time of admission and before percutaneous coronary intervention
  9. Have signed an Informed Consent to participate to the trial before any study related procedure has been taken

Exclusion Criteria:

  1. Cardiac arrest, ventricular fibrillation, cardiogenic shock, stent thrombosis, previous AMI, angina within 48h before admission, previous CABG, treatment with intravenous fibrinolytic therapy within the 72 hours to PCI
  2. Atrial fibrillation (could confound CMR analysis)
  3. Pace-maker
  4. Concurrent inflammatory, infectious or malignant disease
  5. Biliary obstruction or hepatic insufficiency at the time of inclusion in the study
  6. Be possibly dependent on the Investigator or the Sponsor (eg including but not limited to affiliated employee)
  7. Participated in any other investigational drug or therapy study with a non-approved medication, within the previous 3 months
  8. Patient under guardianship
  9. History of egg allergy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Denmark,   France,   Norway,   Sweden
Not Provided
Not Provided
Not Provided
European Commission
Principal Investigator: Dan Atar, Pr Ullevaal University Hospital
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP